Endeavor ™ Drug Eluting Stent: Positive Results Reported

Medtronicreports positive results of the latest study involving its Endeavor™ drug eluting stent, as presented at the American College of Cardiology meeting in Orlando, Florida:

“Overall the clinical results are impressive and show that more than 95 percent of the patients who received an Endeavor stent in the trial required no further treatment or revascularization at the original treatment site at the nine month assessment period,” said Dr. Wijns. “The Endeavor stent’s performance in this trial provides substantial evidence that the Endeavor drug eluting stent is safe and that it substantially reduces clinical restenosis compared to a bare metal stent. These clinical results, taken together with the ease of use of the Driver stent platform, establish the Endeavor stent as a valuable treatment option for patients undergoing angioplasty with drug eluting stents.”
The ENDEAVOR II Clinical Trial, sponsored by Medtronic, Inc. (NYSE: MDT), was a randomized, double-blind pivotal trial designed to evaluate the safety and efficacy of Medtronic’s Endeavor™ Drug Eluting Coronary Stent compared to Medtronic’s Driver™ Cobalt Alloy Coronary Stent in patients with coronary artery disease.
The trial enrolled 1,197 patients at 72 facilities in 17 countries, making it the first and largest drug eluting stent trial comparing a drug eluting stent to a bare metal stent ever performed outside the U.S. The primary endpoint of the trial was TVF at nine months. TVF is a composite endpoint, which includes death, myocardial infarction and Target Vessel Revascularization (TVR). The results from the trial will be used to support Endeavor product approvals globally.

Event Details

PULSUS group cordially welcomes researchers, academicians, students and business professionals in the field of Cancer Science and Therapy from around

more

Event Details

PULSUS group cordially welcomes researchers, academicians, students and business professionals in the field of Cancer Science and Therapy from around the world to participate in the upcoming “2nd World Congress on Advanced Cancer Science & Therapy” to be held at Dubai, UAE during January 28-29, 2019. The meeting for this year will revolve around the theme “An Assembly of Curious Facts and Cure for Cancer” thus relaying the most cutting-edge findings in this field.

The two-day meeting is going to be an event to look forward for its enlightening symposiums & workshops from established experts in cancer therapy, potential keynote talks from eminent speakers, informative oral sessions and innovative poster presentations.

Cancer Therapy 2019 is an extraordinary event that invites participants from different leading universities, clinical research institutions and various diagnostic companies to share their research experiences in all aspects of this rapidly expanding field and provides an opportunity to meet and communicate with leading doctors, surgeons, scientists, academic professionals from around the world and listen to top speakers on new developments that impact and advance future of cancer science. It serves as a global platform to know about the current developments and new approaches in the field of cancer science and therapy. It will also prove to be a brilliant open door for businesses keen on expanding their global market reach. This event is an effort to understand the underlying new techniques which are amended to increase effectiveness, accuracy, sustainability, and quality of life.